Pharma BD Deal Intelligence

LG Chem / Frontier Medicines Corporation

2026 · Licensing/Option · Complete

Frontier Medicines granted LG Chem an exclusive license to develop and commercialize FMC-220, a first-in-class covalent p53 Y220C activator for solid tumors with TP53 loss-of-function mutations, in all territories outside Greater China. Frontier retains ownership and full control of the asset in Greater China. Financial terms were not disclosed beyond an undisclosed upfront payment, clinical/regulatory/commercial milestones, and royalties on net sales ranging from mid-single-digit to double-digit percentages.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals